A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia.

Publisher Website
Google Scholar
Abstract
Olanzapine and other antipsychotics are not approved by the U.S. Food and Drug Administration to treat behavioral disturbances associated with dementia, but they are often prescribed to these patients. Although antipsychotics may be efficacious in this population, elderly patients with dementia may be particularly vulnerable to adverse events. This article reviews the safety of olanzapine in elderly patients with dementia.

This publication has 0 references indexed in Scilit: